Interviews

Ryan Jacobs, MD, of Atrium Health Levine Cancer Institute, explains that the phase 2 CAPTIVATE study's fixed-duration treatment cohort shows long-term progression-free survival for patients with chronic lymphocytic leukemia (CLL) who received the first-line treatment of ibrutinib and venetoclax.

This investigation used data from The US Oncology Network on trends in lung cancer stage when patients present for care.

Catherine Diefenbach, MD, an American Society of Hematology expert and director of the Clinical Lymphoma Program at NYU Langone's Perlmutter Cancer Center, discussed the evolving state of diffuse large B-cell lymphoma (DLBCL) therapeutics and exciting areas of research.

Michael Thorpy, MD, professor of neurology, Albert Einstein College of Medicine, explored the mechanism of action in orexin agonists, which has been indicated for idiopathic hypersomnia.

Brian Koffman, MDCM, DCFP, FCFP, DABFP, MSEd, of CLL Society, details the comprehensive multidisciplinary support for patients with chronic lymphocytic leukemia (CLL) at the European Hematology Association (EHA) 2024 Congress.

Marta Rodríguez Martínez, PhD, sustainability officer of the European Molecular Biology Laboratory, highlights the primary sources of scientific research waste and how to reduce them.

Chesahna Kindred, MD, MBA, FAAD, board-certified dermatologist, Kindred Hair & Skin Center, discusses how diversity in clinical trials are helping bridge the racial health equity gap in psoriasis care.

Kheir Mugwaneza, the lead project manager of the Immigrant and Refugee Health Program at Allegheny Health Network, discusses how the program is working to address gaps in care for this community.

Ali Khawar, principal deputy assistant secretary with the Employee Benefits Security Administration (EBSA), US Department of Labor, explains how the Mental Health Parity and Addiction Equity Act (MHPAEA) aims to address the mental health crisis in the US.

John Hood, PhD, cofounder and CEO of Endeavor BioMedicines, explains the potential advantages of ENV-101 during a time with very few treatments for idiopathic pulmonary fibrosis (IPF).

On this episode of Managed Care Cast, an expert from the University of Minnesota discusses the lack of consideration academic medical centers have for equity when developing governance for AI technologies.

Migvis Monduy, MD, medical director of Neuromuscular and Movement Disorders Programs at Nicklaus Children's Hospital, discussed challenges in Duchenne muscular dystrophy (DMD) treatment access and how policy changes may support patients with DMD.

Jeff Levin-Scherz, MD, MBA, population health leader at WTW, explains that obesity care in the US is inconsistent and costly, with significant gaps across Medicare, Medicaid, and employer-based insurance.

Emily Touloukian, DO, medical oncologist, practice president, and managing partner at Coastal Cancer Center, discusses the importance of patient advocacy when it comes to current issues such as drug shortages and mail order restrictions.

Continuing with our Pride Month podcast series, in this episode we speak with Perry Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, and James F. Dougherty, VMD, MS, current member of Rutgers' Board of Governors.

Experts share what they are looking forward to most at this year's European Hematology Association (EHA) Congress.

Amit Singal, MD, medical director of the Liver Tumor Program at UT Southwestern Medical Center, discussed the current outlook for patients with hepatocellular carcinoma (HCC) and how to choose between therapies.

Several experts that we spoke with for ASCO 2024 share their thoughts on why the American Society of Clinical Oncology annual meeting is so important to the field of oncology.

Speakers at SLEEP 2024, the annual meeting of The American Academy of Sleep Medicine and Sleep Research Society, share their favorite parts of the conference.

Amy Shapiro, MD, medical director, Indiana Hemophilia and Thrombosis Center, discusses an ongoing trial and novel development in plasminogen deficiency type 1.

Allison Brager, PhD, neuroscientist, Walter Reed Army Institute of Research, discusses the interplay between physical exercise and circadian rhythms in improving cardiovascular health.

Ron Grunstein, MD, PhD, head of sleep and circadian research, Woolcock Institute of Medical Research, shares findings from a phase 1b study on the use of a novel orexin agonist in patients with narcolepsy type 1.

Thomas Hall, MD, FAAD, of US Dermatology Partners, explains that disparities in dermatological care arise from the uneven distribution of dermatologists, especially in rural areas, causing delayed diagnoses and higher health care costs.

Michael Thorpy, MD, professor of neurology, Albert Einstein College of Medicine, discusses promising pharmacological treatments for patients with idiopathic hypersomnia.

Ravin Ratan, MD, MEd, MD Anderson, delves into how treatment paradigms and considerations differ between adult patients and pediatric patients who have soft tissue sarcomas.

Hrayr Attarian, MD, professor of neurology, Northwestern Feinberg School of Medicine, shares findings on sleep inequities that have greatly impacted refugees.

The Alliance A091902 trial is currently investigating paclitaxel with and without nivolumab in patients who are taxane naive and nivolumab plus cabozantinib in taxane-pretreated patients.

Caitlin Kindberg, patient advocate in Nashville, Tennessee, discusses her lived experience as an individual with idiopathic hypersomnia, and how the sleep disorder impacts her day-to-day life.

This new analysis of nivolumab presented at ASCO 2024 shows the immune checkpoint inhibitor did not convery benefit when added to a regimen of neoadjuvant carboplatin, paclitaxel, and radiation.

Christopher Depner, PhD, professor of health and kinesiology, University of Utah, shares the challenges of measuring sleep with wearable devices due to nonadherence and the need for metrics like the Sleep Regularity Index.